RE
DNLI icon

RBC Europe’s Denali Therapeutics DNLI Stock Holding History

RBC Europe’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-450
Closed -$22.7K – 755
2021
Q3 		$22.7K Sell
450
-50
-10% -$2.82K ﹤0.01% 754
2021
Q2 		$39.2K Hold
500
– – ﹤0.01% 647
2021
Q1 		$28.6K Hold
500
– – ﹤0.01% 678
2020
Q4 		$41.9K Hold
500
– – ﹤0.01% 562
2020
Q3 		$17.9K Hold
500
– – ﹤0.01% 665
2020
Q2 		$12.1K Hold
500
– – ﹤0.01% 729
2020
Q1 		$8.76K Hold
500
– – ﹤0.01% 740
2019
Q4 		$8.71K Hold
500
– – ﹤0.01% 824
2019
Q3 		$7.66K Sell
500
-215
-30% -$4.11K ﹤0.01% 836
2019
Q2 		$14.8K Hold
715
– – ﹤0.01% 716
2019
Q1 		$16.6K Buy
715
+615
+615% +$12.9K ﹤0.01% 699
2018
Q4 		$2.07K Hold
100
– – ﹤0.01% 1000
2018
Q3 		$2.17K Hold
100
– – ﹤0.01% 1043
2018
Q2 		$1.52K Buy
+100
New +$1.88K ﹤0.01% 1066

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

RBC Europe's DNLI Position: Q4 2021 in Review

RBC Europe sold out of Denali Therapeutics (DNLI) in Q4 2021, closing a stake of 450 shares — an estimated $22.7K sold.

RBC Europe first reported a position in DNLI in Q2 2018 and held it in 14 quarters. The position peaked at $41.9K in Q4 2020. 213 funds tracked by Wall St. Rank hold DNLI as of Q4 2021.

  • RBC Europe reported no remaining Denali Therapeutics position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 450 Denali Therapeutics shares in Q4 2021, an estimated $22.7K.
  • RBC Europe first reported a position in Denali Therapeutics in Q2 2018 and held it in 14 quarters.
  • RBC Europe's Denali Therapeutics position peaked at $41.9K in Q4 2020.
  • 213 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.